OSCR

Magnetically actuated nanoantennas for wireless glioblastoma therapy.

Overview

  1. MIT Media Lab, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
Institutions: MIT Media Lab (United States); Massachusetts Institute of Technology (United States)
Journal: Science advances, volume 12, issue 37, article eaeb1237
Dates: received 31 July 2025; accepted 3 August 2026; published online 9 September 2026; in print September 2026
Type: Research article · Language: English
License: CC BY-NC
Identifiers: DOI 10.1126/sciadv.aeb1237 · PMID 42715333 · PMCID PMC13557086 · OpenAlex W7212019808
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), mouse (organism), other condition (population), clinical / translational (subfield)
Methods: Machine learning, Evoked potentials, Physiology & signal measures, Statistics
MeSH: Brain Neoplasms*, Glioblastoma*, Wireless Technology*, Animals, Cell Line, Tumor, Humans, Mice, Temozolomide, Xenograft Model Antitumor Assays (* major topic)
Topic: Micro and Nano Robotics (Condensed Matter Physics, Physics and Astronomy), according to OpenAlex
Funding: The ChadTough Defeat DIPG Foundation; The Sontag Foundation Distinguished Scientist Award
Citations: not cited yet (Europe PMC); 108 references in the paper

Abstract

Glioblastoma (GBM) remains a formidable clinical challenge, characterized by invasive growth, therapeutic resistance, and dismal patient survival. We report the development of HITMAN (highly localized electric field–induced tumor therapy using magnetically actuated nanoantennas), a wireless bioelectric therapy that selectively eradicates GBM cells with cellular precision. Magnetically actuated nanoantennas convert low-frequency (≤200 kHz), deep-brain–penetrant magnetic fields into localized electric fields, thereby triggering protein unfolding, membrane disruption, and ER stress. In vitro, HITMAN demonstrated superior efficacy compared to temozolomide (TMZ), significantly decreasing viability in drug-resistant, patient-derived GBM cells by 52.2%, versus 10% with TMZ while sparing neurons and astrocytes. Mechanistically, HITMAN activated the unfolded protein response and autophagy pathways, suppressed cell cycle and adhesion genes, reduced Ki-67 expression, disrupted cytoskeletal architecture, and elevated p53 levels, underscoring a multifaceted antitumor mechanism. In orthotopic mouse models, HITMAN significantly inhibited tumor growth, extended median survival by more than 50%, and exhibited no systemic toxicity. Thus, HITMAN offers a minimally invasive, spatially precise, and clinically translatable therapy for GBM.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data, code, and materials availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. RNA-seq data have been deposited in GEO under accession number GSE324656 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324656) (www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE324656). The Mayo Clinic PDX models used in this study can be provided by Mayo Foundation for Medical Education and Research pending scientific review and a completed material transfer agreement with Mayo Foundation for Medical Education and Research. Requests for the PDX models should be submitted to Dr. J. N. Sarkaria at . No new code was generated in this study.

Reproduced under the paper's license (CC BY-NC), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 27 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 10 authors, 9 MeSH terms, 2 funders, 90 references.

Cite

This paper

Saha, M., Khan, I. N., Joy, B., Chen, S.-Y., Yang, H.-T., Patel, P., Jang, K., Zhang, P., Azeemi, F., & Sarkar, D. (2026). Magnetically actuated nanoantennas for wireless glioblastoma therapy. Science advances, 12(37), eaeb1237. https://doi.org/10.1126/sciadv.aeb1237

BibTeX

@article{saha2026magnetically,
author = {Saha, Monochura and Khan, Ishaq N and Joy, Baju and Chen, Shun-Ying and Yang, Hao-Tung and Patel, Preet and Jang, Kyuho and Zhang, Pengrui and Azeemi, Faheem and Sarkar, Deblina},
title = {{Magnetically actuated nanoantennas for wireless glioblastoma therapy}},
journal = {Science advances},
year = {2026},
month = sep,
volume = {12},
number = {37},
pages = {eaeb1237},
publisher = {American Association for the Advancement of Science},
issn = {2375-2548},
doi = {10.1126/sciadv.aeb1237},
url = {https://doi.org/10.1126/sciadv.aeb1237},
pmid = {42715333},
pmcid = {PMC13557086}
}

RIS

TY - JOUR
AU - Saha, Monochura
AU - Khan, Ishaq N
AU - Joy, Baju
AU - Chen, Shun-Ying
AU - Yang, Hao-Tung
AU - Patel, Preet
AU - Jang, Kyuho
AU - Zhang, Pengrui
AU - Azeemi, Faheem
AU - Sarkar, Deblina
TI - Magnetically actuated nanoantennas for wireless glioblastoma therapy
T2 - Science advances
J2 - Sci Adv
PY - 2026
DA - 2026/09/09
VL - 12
IS - 37
SP - eaeb1237
SN - 2375-2548
PB - American Association for the Advancement of Science
DO - 10.1126/sciadv.aeb1237
UR - https://doi.org/10.1126/sciadv.aeb1237
LA - en
ER -

CSL-JSON

{
"id": "10.1126/sciadv.aeb1237",
"type": "article-journal",
"title": "Magnetically actuated nanoantennas for wireless glioblastoma therapy",
"container-title": "Science advances",
"author": [
{
"family": "Saha",
"given": "Monochura"
},
{
"family": "Khan",
"given": "Ishaq N"
},
{
"family": "Joy",
"given": "Baju"
},
{
"family": "Chen",
"given": "Shun-Ying"
},
{
"family": "Yang",
"given": "Hao-Tung"
},
{
"family": "Patel",
"given": "Preet"
},
{
"family": "Jang",
"given": "Kyuho"
},
{
"family": "Zhang",
"given": "Pengrui"
},
{
"family": "Azeemi",
"given": "Faheem"
},
{
"family": "Sarkar",
"given": "Deblina"
}
],
"container-title-short": "Sci Adv",
"volume": "12",
"issue": "37",
"page": "eaeb1237",
"DOI": "10.1126/sciadv.aeb1237",
"PMID": "42715333",
"PMCID": "PMC13557086",
"ISSN": "2375-2548",
"publisher": "American Association for the Advancement of Science",
"URL": "https://doi.org/10.1126/sciadv.aeb1237",
"language": "en",
"issued": {
"date-parts": [
[
2026,
9,
9
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1038/s41378-025-01117-9 [code]
Advancing neural interfaces: a framework for the fabrication and characterization of freestanding micro-nanodevices.
Journal: Microsystems & nanoengineering
In common: 2 references, author Deblina Sarkar
[2] doi:10.1038/s41587-025-02809-3 [code]
A nonsurgical brain implant enabled through a cell-electronics hybrid for focal neuromodulation.
Journal: Nature biotechnology
In common: mouse, 1 reference, author Deblina Sarkar
[3] doi:10.1007/s11011-023-01234-2
Novel sights on therapeutic, prognostic, and diagnostics aspects of non-coding RNAs in glioblastoma multiforme.
Journal: Metabolic brain disease
In common: clinical / translational, other condition, 4 references
[4] doi:10.1038/s41565-024-01798-9 [code]
Magnetoelectric nanodiscs enable wireless transgene-free neuromodulation.
Journal: Nature nanotechnology
In common: mouse, 4 references
[5] doi:10.3389/fimmu.2021.721830
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
Journal: Frontiers in immunology
In common: clinical / translational, other condition, 4 references
[6] doi:10.1038/s41551-025-01409-5 [code]
The cerebellum shapes motions by encoding motor frequencies with precision and cross-individual uniformity.
Journal: Nature biomedical engineering
In common: mouse, author Shun-Ying Chen
[7] doi:10.1038/s44321-024-00091-5
Minimally-invasive implantable device enhances brain cancer suppression.
Journal: EMBO molecular medicine
In common: clinical / translational, other condition, mouse, 3 references
[8] doi:10.1126/sciadv.abq7459
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Journal: Science advances
In common: clinical / translational, other condition, mouse, 4 references
[9] doi:10.1186/s12987-022-00342-y
Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
Journal: Fluids and barriers of the CNS
In common: other condition, 5 references
[10] doi:10.1016/j.xcrm.2026.102850 [code]
Patient-derived organoids predict personalized drug response and reveal alternative therapeutic options in glioblastoma.
Journal: Cell reports. Medicine
In common: clinical / translational, other condition, mouse, 3 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.